RenovaCare, Inc. (RCAR) Income Statement Analysis

See more : Sociedade Comercial Orey Antunes, S.A. (ORE.LS) Income Statement Analysis – Financial Results

Complete financial analysis of RenovaCare, Inc. (RCAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RenovaCare, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

RenovaCare, Inc. (RCAR)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.renovacareinc.com

About RenovaCare, Inc.

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.49K	32.79K	39.85K	51.13K	13.77K	0.00	0.00	0.00	0.00	0.00	919.42K	463.29K	153.71K	0.00	66.43K
Cost of Revenue	0.00	10.97K	22.02K	264.00	317.00	317.00	53.00	0.00	0.00	0.00	32.39K	249.18K	24.99K	42.98K	9.08K	9.83K	56.55K	25.52K	0.00	0.00	226.35K	258.61K	-138.82K	0.00	0.00
Gross Profit	0.00	-10.97K	-22.02K	-264.00	-317.00	-317.00	-53.00	0.00	0.00	0.00	-12.89K	-216.39K	14.86K	8.15K	4.69K	-9.83K	-56.55K	-25.52K	0.00	0.00	693.06K	204.68K	292.53K	0.00	66.43K
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-66.14%	-660.00%	37.29%	15.94%	34.06%	0.00%	0.00%	0.00%	0.00%	0.00%	75.38%	44.18%	190.31%	0.00%	100.00%
Research & Development	0.00	3.20M	4.13M	745.95K	368.95K	574.09K	309.50K	281.22K	975.67K	0.00	0.00	36.85K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	2.20M	5.54M	2.94M	1.64M	2.12M	1.59M	1.04M	1.16M	628.55K	248.60K	536.09K	0.00	312.16K	0.00	7.95K	47.68K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.29K	34.16K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	0.00	2.20M	5.54M	2.94M	1.64M	2.12M	1.59M	1.04M	1.16M	628.55K	248.60K	536.09K	215.46K	312.16K	190.69K	27.24K	81.84K	56.54K	133.67K	579.71K	845.67K	558.77K	967.59K	747.99K	355.02K
Other Expenses	0.00	931.28K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.33K	3.26K	107.16K	0.00	93.44K	375.00	1.06K	14.17K	42.96K	125.32K	125.32K	0.00	0.00	0.00	14.34K
Operating Expenses	0.00	5.41M	9.68M	3.69M	2.01M	2.70M	1.90M	1.32M	2.13M	628.55K	261.93K	576.21K	322.62K	312.16K	284.14K	27.61K	82.90K	70.71K	176.63K	705.03K	970.99K	558.77K	967.59K	747.99K	369.36K
Cost & Expenses	0.00	5.41M	9.68M	3.69M	2.01M	2.70M	1.90M	1.32M	2.13M	628.55K	261.93K	825.39K	347.61K	355.15K	293.22K	27.61K	82.90K	70.71K	176.63K	705.03K	1.20M	817.38K	828.77K	747.99K	369.36K
Interest Income	0.00	6.42K	128.76K	332.24K	22.45K	3.14K	1.03K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.30K	2.93K	1.86K	2.75K	1.58K	5.82K	16.04K	36.13K	86.60K	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	135.27K	996.65K	180.70K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	375.00	1.06K	0.00	0.00	614.00	518.00	0.00	0.00	38.33K	71.06K
Depreciation & Amortization	228.49K	10.97K	22.02K	264.00	317.00	317.00	53.00	1.31K	2.13K	2.22	1.53K	3.26K	4.04M	-1.24M	93.44K	0.00	-36.04K	14.17K	42.96K	125.32K	125.32K	170.89K	183.09K	0.00	0.00
EBITDA	0.00	-5.40M	-9.53M	-3.36M	-2.01M	-2.70M	-1.90M	-1.32M	-2.13M	-628.55K	-239.38K	-786.07K	3.65M	-596.92K	-186.00K	-27.61K	-104.23K	-53.80K	-133.67K	-579.71K	-152.61K	-183.21K	-491.98K	-747.99K	-302.93K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,227.96%	-18,420.46%	9,163.04%	-3,671.87%	-1,350.78%	0.00%	0.00%	0.00%	0.00%	0.00%	-16.60%	-39.54%	-320.06%	0.00%	-456.05%
Operating Income	0.00	-5.41M	-9.68M	-3.69M	-2.01M	-2.70M	-1.90M	-1.32M	-2.13M	-628.55K	-243.96K	-792.60K	-387.01K	-639.91K	-279.45K	-27.61K	-82.90K	-70.71K	-176.63K	-705.03K	-277.93K	-354.09K	-858.15K	-747.99K	-302.93K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,251.46%	-2,417.42%	-971.25%	-1,251.43%	-2,029.39%	0.00%	0.00%	0.00%	0.00%	0.00%	-30.23%	-76.43%	-558.29%	0.00%	-456.05%
Total Other Income/Expenses	0.00	937.69K	128.76K	332.24K	-112.82K	-993.52K	-179.67K	0.00	0.00	0.00	0.00	5.25M	-3.88M	1.91M	14.30K	2.55K	59.23K	2.75K	1.58K	5.21K	15.52K	0.00	0.00	0.00	302.93K
Income Before Tax	0.00	-4.47M	-9.55M	-3.36M	-2.12M	-3.69M	-2.08M	-1.32M	-2.13M	-628.55K	-243.96K	4.46M	-4.35M	1.27M	-372.89K	0.00	-46.87K	-67.97K	-175.05K	-699.82K	0.00	0.00	0.00	0.00	0.00
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,251.46%	13,595.58%	-10,906.67%	2,482.79%	-2,708.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-6.42K	-128.76K	160.64K	22.45K	3.14K	15.22K	-1.31K	-2.13K	404.24K	1.53K	-5.25M	-79.25K	-335.89K	-107.74K	24.68K	-1.86K	0.00	0.00	0.00	-15.52K	-36.13K	96.48K	709.66K	231.88K
Net Income	0.00	-4.47M	-9.42M	-3.36M	-2.12M	-3.69M	-2.08M	-1.32M	-2.13M	-1.03M	-243.96K	4.46M	-4.27M	1.27M	-265.15K	-24.68K	-45.00K	-67.97K	-175.05K	-699.82K	-262.40K	-317.97K	-771.55K	-709.66K	-231.88K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,251.46%	13,595.58%	-10,707.79%	2,482.79%	-1,925.56%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.54%	-68.63%	-501.95%	0.00%	-349.08%
EPS	0.00	-0.05	-0.11	-0.04	-0.03	-0.05	-0.03	-0.02	-0.03	-0.02	0.00	0.07	-0.07	0.02	0.00	0.00	0.00	0.00	0.00	-0.01	-0.02	-0.03	-0.07	-0.03	-0.01
EPS Diluted	0.00	-0.05	-0.11	-0.04	-0.03	-0.05	-0.03	-0.02	-0.03	-0.02	0.00	0.07	-0.07	0.02	0.00	0.00	0.00	0.00	0.00	-0.01	-0.02	-0.03	-0.07	-0.03	-0.01
Weighted Avg Shares Out	0.00	87.35M	87.35M	87.24M	77.75M	74.39M	69.77M	67.23M	66.58M	63.40M	63.08M	63.08M	63.08M	63.08M	59.37M	96.52M	96.63M	96.63M	96.63M	96.63M	15.98M	11.80M	11.80M	23.24M	23.05M
Weighted Avg Shares Out (Dil)	0.00	87.35M	87.35M	87.24M	77.75M	74.39M	69.77M	67.23M	66.58M	63.40M	63.08M	63.08M	63.08M	63.08M	59.37M	96.52M	96.63M	96.63M	96.63M	96.63M	15.98M	11.80M	11.80M	23.24M	23.05M

Pomerantz Law Firm Announces the Filing of a Class Action Against RenovaCare, Inc. and Certain Officers - RCAR

July 22, 2021prnewswire.com

NEW YORK, July 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. ("RenovaCare" or the "Company") (OTCMKTS: RCAR) and certain of its officers. The class action, filed in the United States...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Renovacare, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 14, 2021 - RCAR

July 22, 2021newsfilecorp.com

New York, New York--(Newsfile Corp. - July 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Renovacare, Inc. ("Renovacare") (OTC PINK: RCAR) between August...

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)

July 22, 2021businesswire.com

BENSALEM, Pa.--(BUSINESS WIRE)---- $RCAR #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming September 14, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased RenovaCare, Inc. (“RenovaCare” or the...

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

July 22, 2021newsfilecorp.com

Los Angeles, California--(Newsfile Corp. - July 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

July 22, 2021newsfilecorp.com

RENOVACARE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against RenovaCare, Inc.

July 21, 2021prnewswire.com

NEW YORK, July 21, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of...

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)

July 21, 2021businesswire.com

LOS ANGELES--(BUSINESS WIRE)---- $RCAR #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 14, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired RenovaCare,...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

July 21, 2021newsfilecorp.com

Los Angeles, California--(Newsfile Corp. - July 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC: RCAR) for violations of §§10(b) and...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

July 20, 2021newsfilecorp.com

Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...